Bromide

Bromide

SCHEMBL854064

Br.N=C(N)SCc1ccc(Br)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 17/20 1.00
NOS1 P29475 3/20 0.75
NOS3 P29474 2/20 0.61
NOS2 P35228 2/20 0.61
SLC11A2 P49281 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779731 0.98 IDO1 (1.00) IDO1NOS1NOS3NOS2SLC11A2
SCHEMBL5450413 0.87 NOS1 (1.00) IDO1NOS1NOS3NOS2SLC11A2
SCHEMBL9198311 0.80 NOS1 (0.81) IDO1NOS1NOS3NOS2
Bromide SCHEMBL5042180 0.79 IDO1 (0.96) IDO1NOS1NOS3NOS2
Bromide SCHEMBL4910420 0.79 IDO1 (0.96) IDO1NOS1NOS3NOS2SLC11A2
SCHEMBL27985303 0.79 IDO1 (0.68) IDO1NOS1NOS3NOS2
Benzyl Carbamimidothioate SCHEMBL4911682 0.78 IDO1 (1.00) IDO1NOS1NOS3NOS2SLC11A2
Benzyl Carbamimidothioate SCHEMBL14576763 0.78 IDO1 (1.00) IDO1NOS1NOS3NOS2SLC11A2
Bromide SCHEMBL22263116 0.77 IDO1 (0.62) IDO1NOS1NOS3NOS2SLC11A2
SCHEMBL20677830 0.77 SLC11A2 (0.76) IDO1NOS1NOS3NOS2SLC11A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102827082-B Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO CO LTD 2015-01-07 CN disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-03-13 US disclosed
EP-1775298-B1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY DAIICHI SANKYO CO LTD (JP) 2013-03-20 EP disclosed
EP-2433943-A1 Thienopyrazole derivatives having PDE7 inhibitory activity Daiichi Sankyo Company, Limited (JP) 2012-03-28 EP disclosed
EP-1775298-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY Daiichi Asubio Pharma Co., Ltd. (JP) 2007-04-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140073799-A1 THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY PDE7A, PDE7B, PDE3B IDO1 1810/4885NOS1 264/4885NOS3 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.